Zacks Research Issues Positive Estimate for Avantor Earnings

Avantor, Inc. (NYSE:AVTR) – Analysts at Zacks Research lifted their Q2 2027 earnings estimates for Avantor in a research report issued to clients and investors on Wednesday, May 20th. Zacks Research analyst Team now expects that the company will earn $0.19 per share for the quarter, up from their previous estimate of $0.16. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Avantor’s current full-year earnings is $0.79 per share. Zacks Research also issued estimates for Avantor’s Q4 2027 earnings at $0.23 EPS and FY2027 earnings at $0.84 EPS.

Avantor (NYSE:AVTR) last released its quarterly earnings data on Wednesday, April 29th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.01. Avantor had a negative net margin of 8.42% and a positive return on equity of 9.95%. The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter in the prior year, the company posted $0.23 earnings per share. The business’s revenue was up .0% on a year-over-year basis.

Several other research firms have also issued reports on AVTR. Royal Bank Of Canada initiated coverage on shares of Avantor in a research note on Thursday, May 14th. They issued a “sector perform” rating and a $9.00 target price for the company. Citigroup reduced their target price on shares of Avantor from $11.00 to $9.00 and set a “neutral” rating for the company in a research note on Thursday, April 30th. Wall Street Zen upgraded shares of Avantor from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Barclays reduced their target price on shares of Avantor from $8.50 to $7.00 and set an “underweight” rating for the company in a research note on Tuesday, April 14th. Finally, Robert W. Baird set a $11.00 target price on shares of Avantor in a research note on Thursday, February 12th. Two research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Avantor presently has a consensus rating of “Hold” and an average target price of $10.82.

Avantor Stock Performance

AVTR opened at $7.86 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.17 and a debt-to-equity ratio of 0.68. The company’s fifty day moving average price is $7.95 and its two-hundred day moving average price is $9.88. Avantor has a 1-year low of $7.26 and a 1-year high of $15.93. The company has a market cap of $5.36 billion, a price-to-earnings ratio of -9.70, a PEG ratio of 4.57 and a beta of 0.94.

Hedge Funds Weigh In On Avantor

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AVTR. Wellington Management Group LLP bought a new position in Avantor during the fourth quarter worth about $268,584,000. Greenhaven Associates Inc. bought a new position in Avantor during the third quarter worth about $228,528,000. London Co. of Virginia bought a new position in Avantor during the third quarter worth about $159,669,000. Morgan Stanley boosted its position in Avantor by 179.4% during the fourth quarter. Morgan Stanley now owns 17,468,418 shares of the company’s stock worth $200,188,000 after purchasing an additional 11,216,565 shares during the period. Finally, Engine Capital Management LP boosted its position in Avantor by 65.8% during the first quarter. Engine Capital Management LP now owns 19,780,830 shares of the company’s stock worth $155,082,000 after purchasing an additional 7,853,018 shares during the period. Institutional investors own 95.08% of the company’s stock.

Insiders Place Their Bets

In other Avantor news, Director Sanjeev K. Mehra bought 125,000 shares of the business’s stock in a transaction on Tuesday, March 10th. The stock was purchased at an average price of $8.01 per share, for a total transaction of $1,001,250.00. Following the completion of the transaction, the director directly owned 475,000 shares of the company’s stock, valued at $3,804,750. This trade represents a 35.71% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Simon Dingemans bought 25,000 shares of the business’s stock in a transaction on Friday, May 1st. The shares were acquired at an average price of $8.14 per share, with a total value of $203,500.00. Following the transaction, the director directly owned 25,000 shares of the company’s stock, valued at approximately $203,500. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired 160,000 shares of company stock worth $1,287,950 over the last quarter. 0.28% of the stock is currently owned by company insiders.

More Avantor News

Here are the key news stories impacting Avantor this week:

• Positive Sentiment: Zacks Research raised its Q2 2027 EPS estimate to $0.19 from $0.16, implying improved earnings expectations further out.
• Positive Sentiment: Analysts also lifted Q4 2027 EPS estimates to $0.23 from $0.22, and FY2027 estimates to $0.84 from $0.82, which may support sentiment around Avantor’s longer-term earnings trajectory.
• Positive Sentiment: FY2028 EPS estimates were increased to $0.91 from $0.84, another sign that some analysts see better profitability ahead for Avantor.
• Neutral Sentiment: Zacks Research maintained a Hold rating on Avantor, suggesting the firm is not yet calling for a major re-rating despite the higher estimates.
• Negative Sentiment: Near-term estimates were cut for FY2026, Q2 2026, Q3 2026, and Q1 2027, which can weigh on the shares because investors often focus on the next few quarters first.
• Negative Sentiment: A post-Q1 earnings article questioning whether the stock is a buy, sell, or hold may also reflect continued skepticism about the near-term setup for AVTR. Avantor (AVTR): Buy, sell, or hold post Q1 earnings?

About Avantor

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.